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ABSTRACT 
Nicotine self-administration is associated with decreased expression of the glial 
glutamate transporter 1 (GLT-1) and the cystine-glutamate exchange protein xCT in the 
nucleus accumbens core (NAcore). N-acetylcysteine (NAC), which is an antioxidant, 
anti-inflammatory, and glutamatergic agent, restores these proteins associated with 
increased relapse vulnerability. However, the specific molecular mechanisms driving 
NAC inhibitory effects on cue-induced nicotine reinstatement are unknown. Thus, the 
present study assessed NAC’s effects on cue-induced nicotine reinstatement are 
dependent on NAcore GLT-1 expression. Here, rats were treated with NAC in 
combination with intra-NAcore vivo-morpholinos to examine the role of GLT-1 in NAC-
mediated inhibition of cue-induced nicotine seeking. Subchronic NAC treatment 
attenuated cue-induced nicotine seeking in male rats and an antisense vivo-morpholino 
(AS) designed to selectively suppress GLT-1 expression in the NAcore blocked this 
effect. NAC treatment was also associated with an inhibition of pro-inflammatory tumor 
necrosis factor alpha (TNFα) expression in the NAcore. As well, GLT-1 AS markedly 
increased expression of CD40, a known marker of pro-inflammatory M1 activation of 
microglia and macrophages. To further examine whether NAC-induced decreases in 
nicotine seeking involve suppression of TNFα, we manipulated a downstream mediator 
of this pathway, nuclear factor kappa B (NF-kB). Considering the putative role of NF-κB 
in learning, memory, and synaptic plasticity, separate experiments were performed where 
rats were treated with herpes simplex virus (HSV) vectors designed to increase (HSV-
IKKca) or decrease (HSV-IKKdn) NF-κB signaling through interactions with IκB Kinase 
(IKK). The goal was to examine the role of NF-κB signaling in mediating nicotine 
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seeking behavior and if NF-κB signaling regulates GLT-1 expression. HSV-IKKdn alone 
and in combination with NAC inhibited cue-induced nicotine reinstatement, while HSV-
IKKca blocked the attenuating effect of NAC on reinstatement. Interestingly, both HSV-
IKKdn and HSV-IKKca, regardless of NAC treatment, inhibited GLT-1 expression. 
Taken together, these results suggest that while GLT-1 may be a conserved 
neurobiological substrate underlying relapse vulnerability across drugs of abuse, 
immunomodulatory mechanisms may regulate drug-induced alterations in glutamatergic 
plasticity that mediate cue-induced drug-seeking behavior through GLT-1-independent 
mechanisms. 
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CHAPTER 1 
INTRODUCTION 
 Tobacco Use Disorder, which is characterized by clinical features such as craving, 
tolerance, withdrawal, and unsuccessful quit attempts, is a significant public health 
concern and remains the leading cause of preventable death in the United States, 
accounting for nearly one in five deaths in adults (Danaei et al., 2009; U.S. Department 
of Health and Human Services, 2014). Nearly all adults (88%) who qualify as chronic 
smokers began smoking prior to the age of 18, which is a critical period for the 
development of the brain and is a vulnerable period during which substance use disorders 
and psychiatric co-morbidities can form (Fuhrmann, Knoll, & Blakemore, 2015; Smith, 
McDonald, Bergstrom, Ehlinger, & Brielmaier, 2015; U.S. Department of Health and 
Human Services, 2014). While rates of smoking have continued to decline over the past 
decade, the rise of e-cigarettes and other forms of nicotine consumption (particularly 
among adolescents) highlight the pervasiveness of nicotine and tobacco products as 
potentials risks to public health and safety (Camenga & Klein, 2016). Nicotine, a 
parasympathomimetic alkaloid found in tobacco, is a nicotinic acetylcholine receptor 
(nAChR) agonist and is generally considered the primary psychoactive and reinforcing 
compound in tobacco products (Stolerman & Jarvis, 1995). Current smoking cessation 
treatments primarily function to replace nicotinic stimulation of nAChRs to attenuate 
drug craving without producing rewarding effects (Nides, 2008). For example, 
varenicline (Chantix®) is a partial agonist of α4β2 nAChRs and has shown some clinical 
efficacy in helping individuals quit smoking (Kasza et al., 2015; McClure, Vandrey, 
Johnson, & Stitzer, 2013). Regardless, high rates of relapse persist even for individuals 
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receiving replacement therapy (Leshner & Stapleton, 1997), which highlights the need 
for more effective pharmacotherapies that better promote long-term abstinence from 
tobacco use. 
 The studies described herein attempt to clarify the cellular, molecular, and 
behavioral mechanisms underlying the pharmacotherapeutic N-acetylcysteine (NAC), 
which is an antioxidant, anti-inflammatory, and glutamatergic agent that has 
demonstrated some clinical efficacy in the treatment of substance use disorders and other 
neuropsychiatric conditions (Deepmala et al., 2015; McClure, Gipson, Malcolm, Kalivas, 
& Gray, 2014; Tomko et al., 2018). Below is a detailed review of the relevant literature, 
which examines nicotine-induced alterations in glutamatergic plasticity, the known 
neurobiological mechanisms underlying NAC’s attenuating effects on drug-seeking 
behavior, neuroinflammation as a modulator of glutamatergic plasticity, the clinical and 
preclinical applications of NAC as a therapeutic, and the current gaps in the literature that 
the present studies attempt to address. 
CHAPTER 2 
REVIEW OF THE LITERATURE 
Nicotine activates the mesolimbic reward pathway by stimulating nAChRs on 
dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain, which 
projects to the nucleus accumbens (NA), prefrontal cortex, amygdala, hippocampus, as 
well as several other structures (De Biasi & Dani, 2011; Laviolette & van der Kooy, 
2004; Mansvelder, Keath, & McGehee, 2002; Mansvelder & McGehee, 2002; Placzek, 
Zhang, & Dani, 2009). Specifically, nicotine augments dopamine release through 
activation of α4β2 nAChRs in the VTA (Pidoplichko et al., 2004). However, nicotine may 
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also stimulate the release of dopamine through activation of α6-containing nAChRs (Liu, 
Zhao-Shea, McIntosh, Gardner, & Tapper, 2012), as well as α7 nAChRs located on 
glutamatergic afferents in the VTA (Schilström et al., 2000; Schilström, Svensson, 
Svensson, & Nomikos, 1998). The neurobiological processes mediating the initiation of 
nicotine dependence have been fairly well studied and much has been discovered 
regarding genetic and environmental risk factors that may contribute to the acquisition 
and maintenance of nicotine addiction (Bierut et al., 2008; Changeux et al., 1998; Fowler, 
Lu, Johnson, Marks, & Kenny, 2011; Kuryatov, Berrettini, & Lindstrom, 2011; Stairs, 
Kangiser, Hickle, & Bockman, 2016). Since the discovery of the β2 nAChR subunit’s role 
in the acquisition of nicotine self-administration (Picciotto et al., 1998), drugs such as 
varenicline that stimulate cholinergic signaling have proven clinically efficacious in 
helping individuals quit smoking as mentioned above. Regardless, the cellular 
adaptations and molecular mechanisms underlying vulnerability to nicotine relapse are 
not as thoroughly understood.  
Nicotine-Induced Alterations in Glutamatergic Signaling Underlying Relapse 
Maladaptive glutamatergic plasticity has been implicated across several major drugs 
of abuse (Kalivas, LaLumiere, Knackstedt, & Shen, 2009; Scofield et al., 2016; van 
Huijstee & Mansvelder, 2014). These synaptic alterations mediate the associative 
learning processes that occur between environmental stimuli and drugs of abuse. For 
example, increased prefrontal glutamate release into the NAcore has been shown to 
mediate cue- and drug-induced reinstatement of drug-seeking (Gipson et al., 2013a; 
LaLumiere & Kalivas, 2008; McFarland, Lapish, & Kalivas, 2003; Smith et al., 2017). 
Specifically, glutamatergic projections from the prelimbic cortex (PL) to the NA have 
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been associated with rapid, transient synaptic plasticity during cue-induced reinstatement 
of cocaine- (Gipson et al., 2013a), heroin- (Shen, Moussawi, Zhou, Toda, & Kalivas, 
2011), and nicotine-seeking (Gipson et al., 2013b). Glutamatergic stimulation of medium 
spiny neurons (MSNs) in the NA is critical for mediating reward seeking in response to 
contingent cues (Di Ciano, Cardinal, Cowell, Little, & Everitt, 2001), and chronic 
exposure to drugs of abuse decreases basal levels of extracellular glutamate in the NA 
(Baker, Shen, & Kalivas, 2002).  
The catalytic subunit of the cystine-glutamate antiporter, xCT, is highly expressed in 
astrocytes and provides the majority of basal extracellular glutamate (Baker, Shen, & 
Kalivas 2002; Sato, Tamba, Ishii, & Bannai, 1999). Following self-administration of 
cocaine (Baker et al., 2003) and nicotine (Knackstedt et al., 2009), xCT is downregulated 
and is associated with a decrease in basal extracellular glutamate. This decrease in basal 
levels of glutamate decreases activation of group II metabotropic glutamate receptors (i.e. 
mGluR2/3 receptors), which provide inhibitory tone over glutamatergic afferents in the 
nucleus accumbens (NA). It has been suggested that this loss of tone following chronic 
drug exposure enhances glutamate release during both drug- and cue-induced 
reinstatement of drug-seeking (Baker et al., 2003; Bossert, Busch, & Gray, 2005; 
McFarland et al., 2003; Moran, McFarland, Melendez, Kalivas, & Seamans, 2005). In 
addition to down-regulated cystine-glutamate exchange, chronic drug self-administration 
is associated with a decrease in expression of glutamate transporter 1 (GLT-1) 
(Alhaddad, Das, & Sari, 2014; Gipson et al., 2013b; Knackstedt, Melendez, & Kalivas, 
2010; Sari, Smith, Ali, & Rebec, 2009; Shen, Scofield, Boger, Hensley, & Kalivas, 
2014), which is found predominantly in astrocytes and is responsible for 90% of 
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glutamate uptake in the CNS (Haugeto et al., 1996). Together with system xc-, GLT-1 
serves as a critical regulator of glutamate neurotransmission in the NA and is a putative 
target for treating substance use disorders (Roberts-Wolfe & Kalivas, 2015). 
Neuroinflammation, Glutamatergic Plasticity, and Addiction 
 Neuroinflammation is a consequence of chronic drug abuse that is observed 
across drug classes and has been most extensively studied within alcohol abuse models 
(Crews & Vetreno, 2011). Clinical studies have demonstrated that chronic cigarette 
smoking alters normal innate immune function and can dysregulate normal immune 
responses to inflammatory stimuli, such as through impaired innate and adaptive immune 
responses that result in chronic immune cell activation and blunted immune responses to 
noxious stimuli such as lipopolysaccharide (LPS) (Lee, Taneja, & Vassallo, 2012). 
Importantly, the NF-κB pathway, which is a critical regulator of the innate immune 
system, is activated by cigarette smoking and can directly alter host NF-κB-dependent 
pro-inflammatory responses to infection (Manzel, Shi, O’Shaughnessy, Thorne, & Look, 
2011). Nicotine is a known immunomodulator and, as mentioned previously, a full 
agonist at α7 nAChRs that are expressed ubiquitously on immune cells like microglia and 
macrophages (Shytle et al., 2004). The extant literature on nicotine-induced activation of 
microglial α7 nAChRs generally reports that nicotine promotes an anti-inflammatory 
response, such as reducing pro-inflammatory cytokine release that is triggered by 
inflammatory stimuli (e.g., LPS) (Egea et al., 2015; Suzuki et al., 2006). While the anti-
inflammatory potential of α7 nAChRs is well documented, there are critical gaps in the 
literature that warrant further investigation. For example, Thomsen and Mikkelsen (2012) 
attempted to clarify whether the anti-inflammatory potential of acute nicotine exposure is 
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due to activation or inhibition of nAChRs. In this study, Thomsen and Mikkelsen 
discovered that both agonists and positive allosteric modulators of α7 nAChRs do not 
alter LPS-induced release of the pro-inflammatory cytokine tumor necrosis factor alpha 
(TNFα). In contrast, this study found that the α7 antagonist methyllycaconitine (MLA) 
and a weak agonist both inhibited LPS-induced TNFα release from microglia. These 
findings suggest that the anti-inflammatory potential of nicotine via α7 nAChRs may not 
be through typical ion flux via activation of the receptor. For example, one study 
demonstrated that nicotinic stimulation of microglial α7 can attenuate LPS-induced TNFα 
release through a phospholipase C-dependent mechanism that increases intracellular Ca2+ 
signaling in microglia. However, in the absence of LPS, nicotine alone can dose-
dependently facilitate TNFα release mediated by the adenosine triphosphate receptor 
P2X7 (Suzuki et al., 2006). Given these findings, it is possible that chronic nicotine self-
administration could facilitate TNFα release through such a mechanism. Ultimately these 
studies highlight the inconsistencies in the literature regarding the specific cellular and 
molecular mechanisms of nicotine’s immunomodulatory actions. As well, the distinctions 
between chronic versus acute nicotine and in vitro versus in vivo effects are not fully 
parsed. Thus, investigation of the effects of chronic nicotine self-administration on pro-
inflammatory signaling and subsequent modulation of synaptic plasticity and behavior is 
warranted. 
 TNFα signaling and the NF-κB pathway regulate synaptic plasticity (Albensi & 
Mattson, 2000; Kaltschmidt & Kaltschmidt, 2015; Meffert, Chang, Wiltgen, Fanselow, & 
Baltimore, 2003; O’Neill & Kaltschmidt, 1997), including synaptic plasticity associated 
with addiction-like behaviors (Clark, Wiley, & Bradberry, 2013; Crews & Vetreno, 2011; 
7 
 
Cui, Shurtleff, & Harris, 2014; Gilmore, 2006; Russo et al., 2009). In the canonical 
signaling pathway (as depicted in Figure 6), NF-κB heterodimers (e.g. p50/p65) are 
maintained in an inhibited state within the cytoplasm through interactions with IκB (e.g. 
IκBα). Through ligand binding of extracellular signals (e.g., TNFα) to their cell-surface 
receptors, an IκB kinase (IKK) complex phosphorylates IκBα, triggering the proteasomal 
degradation of IκBα and translocation NF-κB into the nucleus (Gilmore, 2006). Cocaine-
induced alterations in dendritic spine morphology and the acquisition of conditioned 
place preference are mediated by NF-κB signaling, where inhibition of IKK activity 
blocks these drug-induced neurobehavioral adaptations (Russo et al., 2009). As well, 
chronic cocaine markedly induces NF-κB expression in the NA (Ang et al., 2008). 
Interestingly, the β-lactam antibiotic ceftriaxone, which restores glial glutamate transport 
and inhibits cue-induced drug seeking (Alhaddad et al., 2014; Knackstedt et al., 2010; 
Sondheimer & Knackstedt, 2011), increases NF-κB binding at the promoter of the 
excitatory amino acid transporter (EAAT)-2, or GLT-1), resulting in increased expression 
of GLT-1 and glial glutamate uptake (Lee et al., 2008). Notably, GLT-1 undergoes 
differential regulation by NF-κB depending on the extracellular signal that triggers its 
activation, where TNFα promotes transcriptional repression of GLT-1 expression through 
NF-κB activation (Sitcheran, Gupta, Fisher, & Baldwin, 2005). Ceftriaxone also inhibits 
TNFα release in a rat model of traumatic brain injury (Wei et al., 2012). Similarly, NAC, 
which also inhibits drug-induced alterations in synaptic plasticity and cue-induced 
reinstatement (Kupchik et al., 2012; Moussawi et al., 2009; Ramirez-Niño, D’Souza, & 
Markou, 2013; Reissner et al., 2015), has been shown in vitro to inhibit TNFα-induced 
NF-κB activation through inhibition of IKKs (Oka, Kamata, Kamata, Yagisawa, & 
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Hirata, 2000). Thus, drugs such as ceftriaxone and NAC may interact with specific 
components along the NF-κB pathway to restore glutamate homeostasis and inhibit cue-
induced drug seeking. Intriguingly, TNFα rapidly increases GluA2-lacking calcium 
permeable (CP)-AMPAR surface expression and miniature excitatory postsynaptic 
currents in hippocampal slices within 15 minutes of TNFα exposure (Beattie et al., 2002), 
which is the same time point at which Gipson and colleagues observed transient synaptic 
potentiation (t-SP) of medium spiny neurons (MSNs) in the NAcore during cue-induced 
nicotine reinstatement (Gipson et al., 2013b). Moreover, it has been demonstrated that 
glia modulate activity-dependent alterations in synaptic strength through TNFα signaling 
(Stellwagen & Malenka, 2006) and that TNFα uniquely regulates the surface expression 
of both AMPA and GABAA receptors. Specifically, TNFα increases surface expression 
of GluA2-lacking CP-AMPARs and decreases surface expression of GABAA receptors, 
which enhances the excitatory strength of the synapse (Stellwagen, Beattie, Seo, & 
Malenka, 2005). GluA2-lacking CP-AMAPARs are increased during cocaine and 
nicotine withdrawal, and are associated with increased drug seeking and enhanced 
postsynaptic plasticity following exposure to drug-paired cues (Conrad et al., 2008; Wolf 
& Tseng, 2012). 
Clinical and Pre-Clinical Applications of NAC 
The cysteine pro-drug N-acetylcysteine (NAC) is an antioxidant and anti-
inflammatory compound that is commonly used to treat acetaminophen poisoning 
(Yarema et al., 2009). NAC has also been used to treat a multitude of psychiatric 
disorders and neurological diseases, including autism, Alzheimer’s disease, 
trichotillomania, and many others (Deepmala et al., 2015). NAC is thought to drive 
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system xc- and inhibits both drug- and cue-induced reinstatement of drug seeking 
(Kupchik et al., 2012; Moussawi et al., 2009; Ramirez-Niño et al., 2013; Zhou & Kalivas, 
2008). As mentioned previously, reinstatement of drug seeking is associated with 
glutamate release into the NA and a large body of evidence suggests that glutamatergic 
stimulation of postsynaptic mGluR5 receptors potentiates drug-seeking behavior 
(Kumaresan et al., 2009; Moussawi et al., 2009; Smith et al., 2017; Wang, Moussawi, 
Knackstedt, Shen, & Kalivas, 2013). Particularly, NAC-mediated inhibition of cue-
induced cocaine reinstatement depends on restoring homeostatic signaling between 
mGluR2/3 and mGluR5 receptors (Kupchik et al., 2012). Indeed, stimulation of mGluR5 
receptors in the NAcore has been shown to increase cue-induced cocaine reinstatement 
(Wang et al., 2013) and systemic antagonism with 2-methyl-6-(2-phenylethynyl)pyridine 
(MPEP) has been shown to attenuate cue-induced nicotine reinstatement (Bespalov et al., 
2005). Nevertheless, given NAC’s intimate involvement with redox-sensitive signaling 
mechanisms, particularly regarding antioxidant and anti-inflammatory processes, it is 
also likely that its therapeutic efficacy depends on these mechanisms (Elbini Dhouib et 
al., 2016). For instance, chronic cocaine self-administration increases oxidative stress. 
Specifically, cocaine increases S-glutathionylation and decreases the expression of GSH-
S-transferase pi (GSTpi), which has been shown to regulate cocaine-induced 
neurobehavioral plasticity (Uys et al., 2011).  
As mentioned above, drugs such as NAC and ceftriaxone have been shown to 
upregulate both GLT-1 and xCT. As well, restoration of these two proteins is associated 
with decreases in drug- and cue-induced reinstatement of drug seeking (Alhaddad, Das, 
& Sari, 2014; Knackstedt, Melendez, & Kalivas, 2010; Sari, Smith, Ali, & Rebec, 2009; 
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Sondheimer & Knackstedt, 2011). Interestingly, a recent study demonstrated that chronic 
NAC administration successfully inhibits cue-induced cocaine reinstatement when xCT 
expression is suppressed and that chronic NAC treatment is ineffective if GLT-1 is not 
restored (Reissner et al., 2015). In addition, this study also found that inhibition of GLT-1 
expression along with systemic administration of NAC significantly augmented cue-
induced reinstatement, an effect that was blocked by administration of the mGluR5 
negative allosteric modulator 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MTEP) 
(Reissner et al., 2015). Thus, while previous studies would suggest that system xc- 
activity is necessary for NAC to attenuate reinstatement, recent evidence suggests that the 
mechanism through which NAC elicits its therapeutic effects may be more complex. 
Understanding the mechanistic properties of NAC’s therapeutic potential may provide 
useful insights into the molecular underpinnings of cue-induced relapse across drugs of 
abuse. 
Research Aims and Hypotheses 
 Vivo-morpholino and viral-mediated gene transfer strategies were utilized during 
extinction training to manipulate GLT-1 and NF-κB signaling, respectively, to examine 
their role in NAC’s ability to inhibit cue-induced nicotine seeking. We hypothesized that 
NAC would inhibit conditioned nicotine-seeking behavior and that this process is both 
GLT-1- and NF-κB-dependent. Specifically, we predicted that (1) blocking the 
restoration of GLT-1 via NAC would prevent NAC from inhibiting reinstatement and (2) 
that driving NF-κB signaling would also occlude these restorative processes. In addition, 
we hypothesized that NAC treatment and GLT-1 knockdown would alter neuroimmune 
signaling. Therefore, we predicted that (3) NAC treatment would inhibit TNFα 
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expression and that (4) GLT-1 knockdown would elevate CD40 expression (a marker of 
pro-inflammatory activation of microglia and other immune cells). 
CHAPTER 3 
METHODS & MATERIALS 
Subjects 
93 Male Sprague Dawley rats (Charles River, 250-300 g) were individually 
housed on a 12-hour reverse light-dark cycle and received 20 g of food/day and ad 
libitum water. Experimentation was conducted during the dark phase. All experiments 
conducted adhered to the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (2011) and were approved by the Arizona State University 
Institutional Animal Care and Use Committee. 
Drugs and Viral Vectors 
Nicotine tartrate (MP Biomedicals, LLC, Solon, OH, USA) was dissolved in 0.9% 
saline and the pH adjusted to 7.4. Nicotine doses were calculated based on free base 
weight. NAC (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 27 mg/ml sodium 
hydroxide in saline to physiological pH immediately before injection. Vivo-morpholinos 
(Gene Tools, LLC, Philomath, OR, USA) were dissolved in sterile phosphate buffered 
saline (PBS, 10 mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, and 2.7 mM KCl) and 
stored at room temperature. The GLT-1 antisense (AS) vivo-morpholino sequence is 5’-
TGTTGGCACCCTCGGTTGATGCCAT-3’. The reverse sequence was used as a control 
(CTRL). HSV vector titers were as follows: HSV-IKKdn (1.4x108 TU/mL), HSV-IKKca 
(2.0x108 TU/mL), or HSV-GFP (1.9x108 TU/mL). 
Surgical Procedures 
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Rats were anesthetized with ketamine HCL (100 mg/kg, i.m.) and xylazine (8 
mg/kg, i.m.) and underwent surgical implantation of intravenous catheters and 
intracerebral guide cannulae. SILASTIC catheters (Dow Corning, Midland, MI, USA) 
were inserted 3 mm into the right jugular vein, exited subcutaneously through a dermal 
hole between the shoulder blades, and were attached to a stainless-steel cannula held 
within a backpack (Instech Laboratories, Plymouth Meeting, PA, USA). Immediately 
following catheter implantation, rats were fixed onto a stereotaxic frame and intracerebral 
guide cannulae (26G, 15 mm, PlasticsOne, Roanoke, VA, USA) were implanted 
bilaterally into the NAcore (+1.5 A/P, +1.8 M/L, -5.5 D/V, from Paxinos & Watson, 
2007). Cefazolin (100 mg/kg) and meloxicam (1 mg/kg) were administered at the end of 
surgery. Meloxicam was administered for three days following surgery to provide 
analgesia. Cefazolin and heparin (100 usp/kg) were infused through the catheter for seven 
days following surgery and heparin alone was administered daily throughout self-
administration to maintain catheter patency. 
Nicotine self-administration and extinction training 
Behavioral testing took place in operant chambers containing two-levers (an 
active right lever and an inactive left lever), a stimulus light above each lever, and a food 
receptacle (Med Associates, Inc., Fairfax, VT, USA). Prior to surgery and SA procedures, 
rats received a 15 hour food training session where active lever presses dispensed a food 
pellet (45 mg, Bio-Serv, Flemington, NJ, USA) into a receptacle. Food delivery was not 
paired with conditioned cues. Following food training, rats underwent nicotine SA for 2 
hours/day on a fixed-ratio 1 (FR-1) schedule of reinforcement where each active lever 
press resulted in a single infusion of nicotine (0.02 mg/kg/infusion) that was paired with a 
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compound stimulus light and auditory tone followed by a 20-second time-out period. 
Inactive lever presses had no consequence, but responses were still recorded. SA criteria 
were set at a minimum of 10 infusions per session for 10 sessions and a 2:1 active-to-
inactive lever press ratio. Upon completion of SA, rats entered extinction training, where 
active lever presses no longer resulted in nicotine infusions or associated cues. Extinction 
training persisted for 14-16 days prior to a 2-hour cue-induced reinstatement test. Active 
lever presses during reinstatement testing resulted in presentation of nicotine-paired cues 
but not nicotine. Immediately following reinstatement testing, animals were rapidly 
decapitated and NAcore tissue was collected for glutamate uptake, electrophysiology, or 
western blot analysis (described in further detail below). Only animals that extinguished 
to below 65 active lever presses prior to the onset of vivo-morpholino and/or NAC 
treatment were included in the study as described previously (Reissner et al., 2015). 
Microinjection and drug treatment procedures 
Experiment 1 
Beginning on day 10 of extinction training, rats received 3 days of bilateral 
microinjections (1 µl, 0.5 µl/min, 30 pmol/injection) of GLT-1 AS or CTRL sequence 
vivo-morpholino 2-hours following each extinction session. Microinjectors were placed 2 
mm below the guide cannula into the NAcore and were left in place for 1 min following 
the injection to allow for the morpholino to fully diffuse through the tissue. Rats were 
sham injected one day prior to their first microinjection. On days 12 to 16 of extinction, 
rats received NAC (100 mg/kg, i.p.) or saline 2-hours prior to each extinction session. 
This treatment regimen was based on previous studies that demonstrated an increase in 
cystine-glutamate exchange and GLT-1 expression following NAC treatment, a decrease 
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in cue-induced cocaine reinstatement, as well as effective down-regulation of GLT-1 
following morpholino treatment. (Knackstedt, Melendez, & Kalivas, 2010; Moussawi et 
al., 2011; Reissner et al., 2012, 2015). Figure 1A depicts the experimental timeline. 
Experiment 2 
On day 10 of extinction, rats received an acute intra-NAcore microinjection of 
either HSV-GFP, HSV-IKKdn, or HSV-IKKca (1 µl, 0.5 µl/min). Rats were sham 
microinjected the day before receiving HSV. NAC (100 mg/kg, i.p.) was administered for 
5 days beginning on day 10 of extinction exactly as described above. Figure 4A 
illustrates a timeline of the treatment protocol. For both experiments, cannula placement 
was visually inspected prior to tissue collection (as described below) and only animals 
with cannula placement in the NAcore were included in the study. 
Tissue preparation, western blotting, and immunohistochemistry 
Experiment 1 
To examine GLT-1 expression, animals were rapidly decapitated immediately 
following a 2-hour reinstatement test and NAcore tissue was collected and homogenized 
in 200 µl of ice-cold sucrose buffer containing HEPES and sucrose (pH=7.4) and 
supplemented with 1:100 protease and phosphatase inhibitors. Samples were centrifuged 
at 1,000 x g for 10 mins at 4°C, resulting in a pellet that was re-suspended in another 200 
µl of ice-cold sucrose buffer containing 1:100 protease and phosphatase inhibitors. The 
pellet was centrifuged again at 1,000 x g for 10 mins. Supernatants were combined and 
centrifuged at 12,000 x g for 20 mins. The resulting pellet was re-suspended in 30 µl of 
RIPA lysis buffer containing protease and phosphatase inhibitors and centrifuged at 
10,000 x g for 5 mins to remove insoluble matter. To examine CD40 and TNFα 
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expression, NAcore tissue was collected and homogenized in 200 µl of ice-cold RIPA 
lysis buffer and supplemented with 1:100 protease and phosphatase inhibitors. Samples 
were centrifuged at 10,000 x g for 5 mins at 4°C, followed by collection of the 
supernatant.  Protein concentrations were determined by the BCA method (Thermo 
Scientific). Samples were prepared in 4x lithium dodecyl sulfate (LDS) sample buffer 
(Invitrogen) and incubated for 10 mins at 70°C. Equal microgram quantities of protein 
were loaded onto a 4-12% Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose 
membrane using semi-dry transfer conditions for 6 mins (iBlot, Invitrogen). Membranes 
were blocked for 2 hours in tris-buffered saline plus 0.1% Tween-20 (TBST) containing 
5% non-fat milk or bovine serum albumin (BSA) and incubated overnight at 4°C in 
primary antibody (see Table 1). Following incubation, membranes were washed 6 x 5 
mins in TBST, incubated in secondary antibody (see Table 1) for 1 hour at room 
temperature, and washed 6 x 5 mins in TBST. Proteins were detected using ECL 
chemiluminescent substrate (Thermo Scientific) and band density analyzed using NIH 
ImageJ software. Protein expression was normalized to calnexin or GAPDH. 
Experiment 2  
For western blot experiments, tissue was homogenized exactly as described above 
and centrifuged at 10,000 x G for 5 mins at 4°C. Supernatants were collected, processed, 
and probed for GLT-1 exactly as described above. Phosphorylated IκBα (phospho-IκBα) 
and total IκBα expression was also analyzed to verify molecular activity of viral 
constructs. Proteins were detected and normalized to GAPDH as described above and 
densities were analyzed using NIH ImageJ software. To validate viral expression of the 
fluorescent reporter (EGFP) and to confirm neuronal transduction of IKK mutants, 
16 
 
immunohistochemistry was performed. Here, rats were sacrificed via ketamine overdose 
(200 mg/kg, i.p.) for transcardiac perfusion with ice-cold 4% paraformaldehyde (PFA) in 
phosphate buffer (PB) three days after intra-NAcore HSV injection, when viral transgene 
expression is at its peak (Lachmann, 2004). Brains were post-fixed overnight in 4% PFA 
and 30% sucrose for at least 48-hours prior to collection of 40 µm-thick slices of the 
NAcore at 20°C. Slices were washed 3 x 10 mins in phosphate buffered saline (PBS) and 
blocked for 2-hours in 5% normal goat serum (NGS) + PBS + 0.1% Triton X-100 
(PBST). Slices were then incubated overnight at 4°C in anti-GFP (see Table 1) and then 
washed for 3 x 10 mins in PBST. Next, slices were incubated in secondary antibody (goat 
anti-chicken, Alexa Fluor® 488, see Table 1) for 2-hours, washed 3 x 10 mins in PBST, 
and then washed once for 10 mins in PBS. Finally, slices were mounted and cover-
slipped with Vectashield® mounting medium and slides were stored at 4°C until 
analyzed. Images were captured on a confocal microscope at 20x and 63x magnification 
at 488 nm.  
Statistics 
Experiment 1 
Active lever pressing during a 2-hour cue-induced reinstatement test (Figure 1A) 
in morpholino-treated rats that received NAC or vehicle injections was analyzed using a 
two-way ANOVA, with “treatment” (NAC vs vehicle) and “morpholino” (AS versus 
CTRL) as fixed factors. GLT-1 expression (Figure 1D) was similarly analyzed using a 
two-way ANOVA. Lastly, two-way ANOVAs were used to analyze TNFα (Figure 2B) 
and CD40 (Figure 2C) expression, with “treatment” and “morpholino” as fixed factors. 
Post hoc comparisons were made using a Bonferroni or Tukey HSD multiple 
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comparisons test. Significance level was set at α = 0.05 for all analyses using SPSS 
software.  
Experiment 2 
Active lever pressing during a 2-hour cue-induced reinstatement test (Figure 4C) 
in virus-treated rats that received NAC or vehicle injections was analyzed using a two-
way ANOVA, with “treatment” (NAC vs vehicle) and “virus” (HSV-GFP vs HSV-
IKKdn vs HSV-IKKca) as fixed factors. GLT-1 expression (Figure 5) was similarly 
analyzed using a two-way ANOVA. Phospho-IκBα:IκBα expression between HSV-
IKKdn and HSV-IKKca was analyzed using a two-tailed unpaired Student’s t-test. Post 
hoc comparisons were made using a Bonferroni or Tukey HSD multiple comparisons 
test. Significance level was set at α = 0.05 for all analyses using SPSS software.  
CHAPTER 4 
RESULTS 
Experiment 1 
Vivo-morpholino knockdown of GLT-1 impairs NAC-mediated inhibition of cue-induced 
reinstatement 
Here, we hypothesized that GLT-1 AS treatment in the NAcore would impair 
NAC-mediated suppression of cue-induced reinstatement and GLT-1 expression. Figure 
1B depicts lever presses and infusions during nicotine SA and lever presses during 
extinction training. A two-way ANOVA revealed a significant “treatment” X 
“morpholino” interaction (but no main effects of treatment or morpholino alone) (F(1,27) = 
5.978, p = 0.02). Post hoc comparisons revealed a significant decrease in cue-induced 
nicotine reinstatement during a 2-hour session due to NAC treatment, which was blocked 
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by GLT-1 AS (Figure 1C, *p<0.05). Interestingly, rats treated with GLT-1 AS and NAC 
did not reinstate above CTRL-Vehicle conditions as previously reported with cue-
induced cocaine reinstatement (Reissner et al., 2015). A two-way ANOVA examining 
GLT-1 expression revealed significant main effects of “treatment” (F(1,21) = 10.96, 
p<0.001), “morpholino” (F(1,21) = 11.08, p<0.05), and a significant “treatment” X 
“morpholino” interaction (F(1,21) = 4.36, p<0.05). Post hoc comparisons showed that 
CTRL-NAC treatment increased GLT-1 expression in the NAcore relative to all other 
treatment conditions (Figure 1D, *p<0.05). Taken together, these results indicate that 
NAC attenuates cue-induced nicotine seeking behavior and that this mechanism is 
dependent on NAcore GLT-1 expression. 
NAC and vivo-morpholino knockdown of GLT-1 alter neuroimmune signaling in the 
NAcore 
We hypothesized that NAC may modulate glutamatergic plasticity and subsequent 
nicotine-seeking behavior through immunomodulatory mechanisms.  TNFα expression in 
the NAcore was assessed in NAC-treated rats following cue reinstatement, regardless of 
morpholino treatment. A two-way ANOVA revealed a significant main effect of 
“treatment” on TNFα expression (F(1,29) = 8.77, p<0.05). Post hoc comparisons revealed 
that NAC treatment, regardless of morpholino, significantly attenuated TNFα expression 
(Figure 2B, *p<0.05). Furthermore, a two-way ANOVA revealed a significant main effect 
of “morpholino” on CD40 expression (F(1,27) = 38.40, p<0.001). Post hoc comparisons 
indicated that regardless of NAC treatment, GLT-1 AS alone was sufficient to upregulate 
CD40 (predominantly expressed by microglia and other immune cells in the CNS 
(Kawahara et al., 2009)) (Figure 2C, *p<0.05). Together, these results suggest that while 
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NAC inhibits NAcore TNFα, suppressing GLT-1 may exacerbate microglial activation 
regardless of NAC treatment.  
Experiment 2 
Validation of viral constructs  
Prior to examining the neurobehavioral effects of NF-κB manipulation on cue-induced 
nicotine reinstatement, we sought to validate the neurotropism and functional activity of 
HSV vectors. Rats receiving HSV-IKKca exhibited significantly elevated phosphorylation 
of IκBα compared to HSV-IKKdn-treated rats (Figure 3D, t(14) = 2.38, p = 0.032) three 
days post-injection. In addition, confocal microscopy performed on fixed NAcore tissue 
revealed successful viral transduction and expression of the GFP reporter within NAcore 
MSNs (Figures 3A-C). 
NF-κB signaling in the NAcore regulates cue-induced nicotine seeking and NAC’s 
attenuating effects on nicotine seeking behavior 
 In this experiment, we hypothesized that constitutive activation of NF-κB would 
impair NAC-mediated attenuation of cue-induced nicotine reinstatement as well as inhibit 
GLT-1 expression in the NAcore. Figure 4B depicts lever presses and infusions during 
self-administration and lever presses during extinction training. A two-way ANOVA 
revealed a significant main effects of “treatment” (F(1,38) = 18.74, p < 0.001) and “virus” 
(F(2,38) = 13.341, p < 0.001), as well as a significant “treatment” X “virus” interaction (F(2,38) 
= 9.938, p < 0.001) on active lever presses during a 2-hour cue reinstatement test (Figure 
4C). Post hoc analyses revealed that rats receiving HSV-GFP + Vehicle, HSV-IKKca + 
NAC, and HSV-IKKca + Vehicle all significantly reinstated relative to extinction and 
displayed significantly higher reinstatement compared to the other treatment conditions (p 
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< 0.05). These results indicate that the inhibition of cue-induced nicotine reinstatement by 
NAC is sensitive to NF-κB signaling, which suggests that the therapeutic efficacy of NAC 
may depend on its immunomodulatory activity described in Experiment 1. 
NF-κB signaling regulates GLT-1 expression in the NAcore following nicotine self-
administration and extinction 
Considering that constitutive activation of NF-κB occluded the inhibitory effects of NAC 
on reinstatement, we hypothesized that HSV-IKKca, regardless of NAC treatment, would 
result in impaired GLT-1 expression in the NAcore. A two-way ANOVA revealed a 
significant main effect of “virus” (F(2,34) = 12.103, p < 0.001), with no significant main 
effect of “treatment” or “treatment” X “virus” interaction (Figure 5). Post hoc analysis of 
“virus” revealed significantly higher GLT-1 expression in GFP-treated rats compared to 
both HSV-IKKdn- and HSV-IKKca-treated rats (p < 0.001). Taken together, these results 
indicate that NAC itself did not alter total levels of GLT-1 expression, but that constitutive 
activation or inhibition of NF-κB may suppress GLT-1 expression regardless of NAC 
treatment. 
CHAPTER 5 
DISCUSSION 
GLT-1 Mediates the Inhibitory Effects of NAC on Cue-Induced Nicotine Seeking 
The present findings indicate that GLT-1 expression is necessary for NAC to 
inhibit cue-induced nicotine seeking.  The inhibition of GLT-1 expression using an 
antisense vivo-morpholino (GLT-1 AS) significantly suppressed GLT-1 protein levels in 
the NAcore even in the presence of NAC. This suppression of GLT-1 expression was 
associated with an increase in cue-induced nicotine reinstatement. Unlike what has been 
21 
 
observed with cue-induced cocaine reinstatement (Reissner et al., 2015), the combination 
of GLT-1 AS and NAC did not augment reinstatement significantly above what was 
observed in vehicle controls. Downregulation of GLT-1 is a consistent drug-induced 
neuroadaptation that has been observed across drug classes (Alhaddad, Das, & Sari, 
2014; Gipson et al., 2013b; Knackstedt, Melendez, & Kalivas, 2010; Roberts-Wolfe & 
Kalivas, 2015; Sari, Smith, Ali, & Rebec, 2009; Shen, Scofield, Boger, Hensley, & 
Kalivas, 2014), and restoration of GLT-1 expression is associated with a decrease in cue-
induced cocaine reinstatement (Knackstedt, Melendez, & Kalivas, 2010; Trantham-
Davidson, LaLumiere, Reissner, Kalivas, & Knackstedt, 2012). Given these previous 
findings and the current results, up-regulation of GLT-1 via NAC may inhibit cue-
induced nicotine seeking akin to cue-induced cocaine seeking. However, considering 
NAC did not potentiate reinstatement when GLT-1 levels were suppressed, the 
mechanism by which NAC inhibits cue-induced nicotine reinstatement may not be 
entirely analogous to that of cue-triggered cocaine seeking. Provided that inhibiting GLT-
1 expression and driving cystine-glutamate exchange increased extracellular glutamate 
concentrations, it is likely that mGluR2/3 stimulation would have increased, thereby 
decreasing presynaptic glutamate release. Therefore, the reinstatement of nicotine 
seeking observed in rats treated with NAC and GLT-1 AS may not be the consequence of 
solely inhibiting GLT-1 expression. Indeed, GLT-1 knockdown may have neuroimmune 
consequences that could alter synaptic plasticity, as described below. While nicotine self-
administration shares common neurobiological consequences with other drugs of abuse, 
nicotine differentially alters NAcore proteins associated with glutamatergic signaling as 
compared to cocaine and heroin (e.g., AMPA and NMDA receptor subunit composition 
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Conrad et al., 2008; Gipson et al., 2013b; Shen et al., 2011). Taken together, the present 
findings highlight the need to examine nicotine-specific mechanisms underlying cue-
triggered nicotine relapse in order to improve treatment outcomes and guide the 
development of new and effective pharmacotherapies. 
NAC Inhibits TNFα Expression and GLT-1 Knockdown Upregulates CD40  
 Regardless of morpholino treatment, rats treated with NAC exhibited an 
attenuation of pro-inflammatory TNFα expression in the NAcore relative to vehicle-
treated controls. In addition, rats treated with GLT-1 AS, regardless of NAC treatment, 
exhibited enhanced CD40 expression, which is a marker of pro-inflammatory (M1) 
activation of microglia, macrophages, and other immune cells (Walker & Lue, 2015). 
These findings corroborate previous studies that have demonstrated the anti-
inflammatory potential of NAC (Oka et al., 2000; Schneider et al., 2017; Sury et al., 
2006) as well as the role of dysregulated glutamatergic signaling in neuroinflammatory 
disease processes (Kaindl et al., 2012; Noda & Beppu, 2013; Wei et al., 2012). Indeed, 
the interactions between TNFα, CD40, and NF-κB are complex. Previous work has 
suggested that transcriptional activation of CD40 is mediated by interferon gamma (IFN-
γ), which also induces TNFα production and subsequent activation of NF-κB (a 
transcriptional regulator of CD40) similar to pathological levels of extracellular 
glutamate (Benveniste, Nguyen, & Wesemann, 2004). While microglia do not produce 
significant levels of IFN-γ, peripheral immune cells (i.e., T-cells) that infiltrate into the 
brain parenchyma due to drug-induced disruptions of the blood brain barrier (Clark et al., 
2013; Hawkins et al., 2004) do release IFN-γ. This positive feedback loop results in a 
robust immune response that may increase extracellular glutamate through TNFα-induced 
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downregulation of GLT-1 (Olmos & Lladó, 2014; Sitcheran et al., 2005). Overall, this 
cascade of pro-inflammatory events could result in enhanced postsynaptic excitatory 
potential in MSNs within the NAcore, which could be a driving force underlying both 
cue-induced drug-seeking behavior as well as persistent dysregulation of glutamatergic 
signaling. 
Nicotine, as opposed to other drugs of abuse, is capable of directly modulating 
neuroimmune signaling in the CNS through its full-agonist activity at the α7 nAChR. 
Cholinergic activity at α7 nAChRs on microglia plays a significant role in modulating 
microglial responses to inflammatory stimuli, where acute nicotinic activation of 
microglial α7 exerts an anti-inflammatory effect (Shytle et al., 2004). However, nicotine 
exposure can also disrupt the blood brain barrier as mentioned above (Hawkins et al., 2004) 
and induce oxidative stress and NF-κB activation (Barr et al., 2007). Here, we demonstrate 
that subchronic NAC treatment significantly attenuated pro-inflammatory TNFα 
expression in the NAcore, which was measured immediately after a 2-hour cue 
reinstatement test (Figure 2B). TNFα, which is a known modulator of learning, memory, 
and glutamatergic plasticity (Albensi & Mattson, 2000; Beattie et al., 2002; Stellwagen, 
Beattie, Seo, & Malenka, 2005; Stellwagen & Malenka, 2006), is primarily derived from 
microglia under pathological conditions (Gregersen, Lambertsen, & Finsen, 2000; Welser-
Alves & Milner, 2013). Indeed, our results corroborate previous findings indicating an 
inhibitory effect of NAC on brain TNFα expression (Oka et al., 2000; Saleh, 2015; Sury et 
al., 2006). Moreover, microglia are known to express both ionotropic and metabotropic 
glutamate receptors that mediate neuroinflammatory processes (Biber et al., 2001; Kaindl 
et al., 2012; Noda & Beppu, 2013). Interestingly, TNFα both increases surface expression 
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of GluA2-lacking calcium permeable AMPA receptors and decreases surface expression 
of GABAA receptors within hippocampal slices, resulting in significant increases in 
excitatory synaptic strength (Stellwagen et al., 2005). This effect was shown to occur 
within 15 minutes of TNFα treatment, which is the same time point at which we have 
previously observed rapid post-synaptic potentiation of MSNs during cue-induced nicotine 
reinstatement (Gipson et al., 2013b). Recently, it has been suggested that TNFα might 
decrease excitatory activity at striatal synapses and inhibit cocaine-induced synaptic 
plasticity (Lewitus et al., 2016). However, this study did not utilize a range of 
physiologically-relevant concentrations of TNFα (compare to Habbas et al., 2015), and 
utilized 5 days of experimenter-delivered cocaine as opposed to SA, which are different 
models of drug delivery that produce profoundly distinct neurobehavioral consequences 
(Namba, Tomek, Olive, Beckmann, & Gipson, 2018). For example, nicotine SA, but not 
experimenter-delivered nicotine, decreases GLT-1 in the NAcore (Gipson et al., 2013b; 
Knackstedt et al., 2009). Taken together, it is possible that nicotine, through its direct 
actions on microglial nAChRs, could uniquely alter stimulus-induced neuroimmune 
activity that functions as a modulator of glutamatergic plasticity and subsequent drug-
seeking behavior. 
As highlighted above, microglial sensitivity to changes in extracellular glutamate 
may underlie a significant immunomodulatory mechanism that shapes neuron-glia 
crosstalk and subsequent drug-seeking behavior. Interestingly, exogenous glutamate has 
been shown to rapidly increase glutamate uptake within 15 minutes of exposure in vitro 
(Duan, Anderson, Stein, & Swanson, 1999). Thus, an activity-dependent compensatory 
immunomodulatory mechanisms that are sensitive to rapid elevations in extracellular 
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glutamate may underlie relapse-dependent neurobehavioral plasticity. Considering TNFα 
downregulates GLT-1 through activation of NF-κB (Sitcheran et al., 2005), it is possible 
that glutamate overflow-induced activation of microglia and subsequent release of TNFα 
could produce long-lasting inhibition of GLT-1 expression. We demonstrate here that rats 
treated with GLT-1 AS morpholino exhibited marked elevations in CD40 expression 
(Figure 2C), which is a known marker of pro-inflammatory M1 activation of microglia and 
other immune cells (Walker & Lue, 2015). Assuming GLT-1 knockdown contributed to 
elevated levels of extracellular glutamate and impaired glial glutamate uptake, it is possible 
that this could explain the significant increase in CD40 expression observed in antisense-
treated rats. Thus, despite treatment with NAC and inhibition of TNFα, pro-inflammatory 
activation of microglia induced by GLT-1 knockdown is a possible mechanism that might 
explain why GLT-1 antisense occluded the therapeutic efficacy of NAC as observed in the 
present study. 
NF-κB Signaling Regulates Both GLT-1 Expression and Cue-Induced Nicotine 
Seeking 
 As an extension of the aforementioned findings, we sought to examine the 
specific role of NF-κB in regulating cue-induced nicotine seeking as well as the 
therapeutic efficacy of NAC. Rats receiving HSV-IKKdn demonstrated an attenuation of 
cue-induced reinstatement, regardless of NAC treatment. Conversely, rats receiving a 
HSV-IKKca reinstated nicotine seeking in response to contingent cues. Interestingly, 
HSV-IKKca also blocked the attenuating effects of NAC on cue-induced reinstatement. 
Combined with the above findings that NAC inhibits TNFα expression, these results 
suggest that inhibition of pro-inflammatory activation of NF-κB may be a defining 
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mechanism underlying NAC’s therapeutic efficacy. Surprisingly, while HSV-IKKdn 
alone was sufficient to inhibit cue-induced reinstatement, it inhibited GLT-1 expression 
similar to HSV-IKKca-treated conditions, regardless of NAC treatment. Overall, these 
findings suggest that while NF-κB regulates NAC’s effects on cue-induced nicotine 
seeking and GLT-1 expression, NF-κB may also mediate nicotine-seeking behavior 
through GLT-1-independent mechanisms. While seemingly inconsistent with the 
aforementioned findings from Experiment 1, this conclusion is supported by recent 
findings demonstrating that AAV-mediated overexpression of GLT-1 is insufficient to 
inhibit cue-induced cocaine reinstatement (Logan, LaCrosse, & Knackstedt, 2018). 
 TNFα signaling and the NF-κB pathway regulate learning, memory, and synaptic 
plasticity (Albensi & Mattson, 2000; Kaltschmidt & Kaltschmidt, 2015; Meffert et al., 
2003; O’Neill & Kaltschmidt, 1997), including synaptic plasticity associated with drug-
seeking behavior (Ang et al., 2008; Clark et al., 2013; Crews, Zou, & Qin, 2011; Cui et 
al., 2014; Russo et al., 2009). Here, we confirm that inhibiting NF-κB alone is sufficient 
to inhibit cue-induced nicotine seeking despite concomitant downregulation of GLT-1. 
As mentioned previously, NF-κB is a bidirectional regulator of GLT-1 (Sitcheran et al., 
2005). Therefore, it is reasonable to posit that constitutive activation (by HSV-IKKca) or 
dominant negative inhibition (by HSV-IKKdn) of NF-κB could result in a net decrease in 
GLT-1 expression. Indeed, NF-κB signaling has been shown to be necessary for neuron-
dependent induction of GLT-1 expression in astrocytes (Ghosh, Yang, Rothstein, & 
Robinson, 2011). Nevertheless, our results support a previous study that demonstrated 
that NF-κB signaling in the nucleus accumbens facilitates cocaine-induced changes in 
dendritic spine morphology as well as the formation of cocaine conditioned place 
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preference (Russo et al., 2009). Considering the finding that HSV-IKKca blocked the 
inhibitory effect of NAC on cue-induced nicotine reinstatement and that these HSV 
vectors produced transgene expression in MSNs (Figure 3A-C), it is possible that NAC 
may inhibit cue-triggered relapse through inhibition of pro-inflammatory activation of 
neuronal NF-κB. Figure 6 provides an illustration of a proposed mechanism of action 
through which NAcore glutamate overflow induced by exposure to drug-paired cues 
could activate microglia and a pro-inflammatory signaling cascade that ultimately 
facilitates nicotine-seeking behavior. 
Alternative Potential Mechanisms Underlying the Effects of NAC 
Previous work has demonstrated that high concentrations of NAC in vitro 
increase excitatory postsynaptic currents (EPSCs) on MSNs via activation of mGluR5, 
whereas low concentrations of NAC decrease EPSCs on MSNs through an increase in 
cystine-glutamate exchange and subsequent stimulation of presynaptic mGluR2/3 
receptors (Kupchik et al., 2012). Other studies have also indicated that glutamatergic 
signaling between system xc- and presynaptic mGluR2/3 receptors mediates the effects of 
NAC on cocaine reinstatement (Kau et al., 2008; Moran et al., 2005). Additionally, a 
recent study has shown that inhibiting GLT-1 expression and chronically administering 
NAC potentiates cue-induced cocaine reinstatement through activation of mGluR5 
(Reissner et al., 2015). Considering chronic nicotine exposure is associated with a 
decrease in system xc- function and mGluR2/3 expression (Knackstedt et al., 2009; 
Liechti, Lhuillier, Kaupmann, & Markou, 2007), and cue-induced nicotine reinstatement 
is associated with an increase in extracellular glutamate (Gipson et al., 2013b), it is likely 
that extracellular glutamate levels were increased in rats treated with NAC and GLT-1 
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AS. While not directly quantified in the present study, this potential elevation in 
extracellular glutamate could have increased postsynaptic excitability via mGluR5, 
effectively blocking the observed inhibitory effects of NAC on cue-induced nicotine 
reinstatement. However, the lack of potentiation of reinstatement in rats treated with 
NAC and GLT-1 AS suggests that alternative, nicotine-specific neurobiological 
mechanisms may underlie NAC’s therapeutic potential, as highlighted above. 
Group I metabotropic glutamate receptors have been implicated in nicotine 
seeking behavior and antagonism of mGluR1/5 receptors has been shown to inhibit 
nicotine self-administration (Paterson, Semenova, Gasparini, & Markou, 2003; Tronci, 
Vronskaya, Montgomery, Mura, & Balfour, 2010) as well as cue- and nicotine-induced 
reinstatement (Bespalov et al., 2005; Dravolina et al., 2007). However, the role of these 
receptors on conditioned behavior is not uniform. Studies have demonstrated that, unlike 
cocaine, the reward-enhancing effects and the conditioned-rewarding effects of nicotine 
are not reduced by antagonism of mGluR5 receptors (McGeehan & Olive, 2003; 
Palmatier, Liu, Donny, Caggiula, & Sved, 2008). Given the present findings, the potential 
role of mGluR5 in cue-induced nicotine reinstatement after suppressing GLT-1 
expression and driving cystine-glutamate exchange remains somewhat unclear. 
Therefore, future studies should examine the impact of mGluR5 antagonism on cue-
induced nicotine reinstatement in rats treated with NAC and GLT-1 antisense vivo-
morpholino. 
Concluding Remarks 
Clinical studies investigating NAC as a treatment for substance use disorders have 
shown inconsistent results. One study investigating NAC in cocaine-dependent 
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individuals found that NAC may suppress cocaine withdrawal and craving (LaRowe et 
al., 2006), while another more recent study found that NAC did not suppress cocaine use 
unless individuals had achieved abstinence prior to the onset of treatment (LaRowe et al., 
2013). Similarly, another study showed that NAC demonstrated a trend towards reducing 
withdrawal symptoms in nicotine-dependent individuals but had no effect on nicotine 
craving (Schmaal et al., 2011). Additionally, an earlier placebo-controlled study showed 
that NAC had no effect on nicotine craving or withdrawal and only showed a decrease in 
self-reported cigarette use per day when two outliers were removed due to excessive 
alcohol consumption (Knackstedt et al., 2009). Considering these findings, it is likely that 
NAC may be most effective in preventing relapse during a period of abstinence. Indeed, 
most preclinical studies implicating NAC as a potentially effective pharmacotherapeutic 
have utilized a model of reinstated drug seeking, where animals are placed into extinction 
training or forced abstinence following drug self-administration. In addition to NAC’s 
effects on GLT-1 and cystine-glutamate exchange, NAC also exhibits antioxidant and 
anti-inflammatory properties that may underlie its observed therapeutic effects on cue-
induced nicotine reinstatement (Zafarullah, Li, Sylvester, & Ahmad, 2003). For instance, 
pro-inflammatory TNFα recruits NF-κB to inhibit GLT-expression (Sitcheran et al., 
2005). Interestingly, NAC has been demonstrated to inhibit TNFα-induced activation of 
NF-κB (Oka et al., 2000). Ceftriaxone has also been shown to increase GLT-1 expression 
through a NF-κB-dependent mechanism (Lee et al., 2008). Finally, as demonstrated in the 
aforementioned studies, inhibition of pro-inflammatory activation of NF-κB is likely a 
relevant mechanisms underlying NAC’s therapeutic mechanism, which includes its 
restorative effects on glutamatergic signaling. Intriguingly, a recent report has 
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demonstrated that enhancing NAC’s bioavailability via nanoparticles significantly 
improves its anti-inflammatory potential (Markoutsa & Xu, 2017). NAC is notorious for 
its poor oral bioavailability and patients in clinical settings must take large doses to 
achieve the desired therapeutic outcome, which represents a significant limitation of 
NAC as a therapeutic (McClure et al., 2014; Minarini et al., 2017). Given the present 
findings, which highlight the role of immunomodulation in regulating nicotine-seeking 
behavior, improving NAC’s bioavailability may enhance its anti-inflammatory potential 
and thus its therapeutic efficacy. As such, future studies should further investigate the 
potential role of neuroimmune function in modulating relapse-dependent synaptic 
plasticity and subsequent drug-seeking behavior, which may yield valuable insight into 
the cellular and molecular mechanisms that drive addiction and relapse processes. 
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Figure 1. GLT-1 Knockdown Impairs NAC Inhibition of Cue-Induced Reinstatement. 
(A) Timeline of experimental procedures. (B) Rats self-administered nicotine (0.02 
mg/kg/infusion) on an FR-1 schedule until criteria were met. Following self-
administration, rats were placed into extinction training, where some received once-daily 
vivo-morpholino microinjections between days 10 and 12, followed by NAC (100 mg/kg, 
i.p.) or vehicle injections between days 12 and 16. (C) Average active lever presses 
during the last two extinction sessions and during a 2-hr cue-induced nicotine 
reinstatement session (26 hours following last NAC injection). NAC significantly 
attenuated active lever pressing relative to saline controls. This effect was blocked by 
administration of GLT-1 antisense vivo-morpholino. *p < 0.05 and #p < 0.10. (D) GLT-1 
expression across treatment groups, normalized to CTRL-Vehicle (denoted by dashed 
line). NAC significantly increased GLT-1 protein expression as compared to vehicle 
controls. Additionally, GLT-1 antisense vivo-morpholino suppressed GLT-1 levels in 
NAC-treated rats. *p < 0.05. Error bars = SEM. 
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Figure 2. Nicotine Self-Administration and GLT-1 Knockdown Alter Neuroimmune 
Signaling. (A) Timeline of experimental procedures. (B) TNFα expression following 
nicotine SA, extinction, and cue-induced reinstatement. NAC significantly inhibited 
TNFα expression measured after reinstatement. *p < 0.05. (C) CD40 expression 
following nicotine self-administration, extinction, and cue-induced reinstatement. GLT-1 
antisense morpholino treatment significantly elevated CD40 expression measured after 
reinstatement. *p < 0.05. Error bars = SEM. 
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Figure 3. Validation of Viral Constructs. (A) HSV-IKKca and (B) HSV-IKKdn 
successfully produce GFP expression in the NAcore. (C) Moreover, HSV vectors 
successfully produce transgene expression in NAcore MSNs. (D) Compared to HSV-
IKKdn, HSV-IKKca produces significantly more phosphorylation of IκBα, which is a 
protein that normally keeps NF-κB in an inhibited state in the cytoplasm until it is 
phosphorylated. *p < 0.05. Error bars = SEM. 
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Figure 4. Constitutive Activation of IKK Blocks Attenuating Effect of NAC on Cue-
Induced Nicotine Seeking. (A) Timeline of experimental procedures. Rats underwent 
nicotine self-administration and extinction exactly as described in Experiment 1, except 
on Day 10 of extinction, rats received an intra-NAcore microinjection of HSV-GFP, 
HSV-IKKdn, or HSV-IKKca. NAC or vehicle injections also began on Day 10 and 
persisted through the end of extinction. (B) Lever presses and nicotine infusions across 
self-administration and lever presses across extinction training. (C) Average active lever 
presses during the last two extinction sessions and during a 2-hr cue-induced nicotine 
reinstatement session (26 hours following last NAC injection). Rats receiving HSV-GFP 
+ Vehicle, HSV-IKKca + Vehicle, or HSV-IKKca + NAC significantly reinstated 
nicotine seeking in response to contingent cues as compared to the other three treatment 
conditions. #p < 0.05 relative to HSV-GFP + NAC, HSV-IKKdn + NAC, and HSV-
IKKdn + Vehicle. *p < 0.05 relative to respective extinction. Error bars = SEM. 
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Figure 5. Constitutive Activation or Inhibition of IKK in the NAcore Inhibits GLT-1 
Expression. NAC treatment within the HSV-GFP control condition did not increase total 
GLT-1 protein levels in the NAcore above the vehicle condition. Regardless of NAC or 
Vehicle treatment, both HSV-IKKca and HSV-IKKdn inhibited GLT-1 expression 
compared to HSV-GFP controls.*p < 0.001. Data normalized to HSV-GFP, denoted by 
dotted line. Error bars = SEM. 
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Figure 6. Proposed Mechanism of Action of Immunomodulatory Mechanisms Regulating 
Relapse-Induced Glutamatergic Plasticity. (1) Cue-induced reinstatement induced 
glutamate (Glu) release into the NAcore from prelimbic cortex (PLC) afferents, which 
synapse with NAcore MSNs. (2) This causes glutamate overflow into the extracellular 
space, which could (3) activate resident microglia through stimulation of ionotropic 
glutamate receptors, leading to (4) NF-κB activation and (5) TNFα release. Once 
released, TNFα can bind to TNF receptor 1 (TNFR1) on (6) astrocytes, leading to (7) 
further downregulation of GLT-1 and (8) MMP activation. As well, TNFα can bind to 
TNFR1 on neurons, leading to (9) neuronal NF-κB activation and (10) subsequent 
increases in dendritic spine diameter (dh) and/or density, transient synaptic potentiation 
(t-SP), and motor output. 
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Table 1         
       
Antibody Concentrations for Western Blot 
Experiments    
Target Catalog # RRID 10 Concentration 
20 
Concentration 
GLT-1 Abcam ab41621 AB_941782 1:1,000 1:45,000 
CD40 Abcam ab13545 AB_1951619 1:1,000 1:5,000 
TNFα Abcam ab6671 AB_305641 1:1,000 1:2,000 
Calnexin Enzo ADI-SPA-860 AB_10616095 1:1,000 1:25,000 
GAPDH CST D16H11 AB_10622025 1:1,000 1:25,000 
Note. All secondaries were Goat pAb to Rb IgG (HRP) (Abcam ab97080; RRID: 
AB_10679808) 
 
